GSK and Biological E. announce joint venture to develop combination vaccine for India and other developing countries
28 January 2013 | By GlaxoSmithKline
GSK and Biological E. announced an agreement to form a 50/50 joint venture...
List view / Grid view
News
Amgen announces results from Phase 3 PAVES Study evaluating Neulasta® in patients with colorectal cancer
26 January 2013 | By Amgen
Results from Pegfilgrastim and Anti-VEGF Evaluation Study...
Pfizer receives FDA approval for the use of Prevnar 13
25 January 2013 | By Pfizer
Prevnar 13 is the first and only pneumococcal conjugate vaccine approved for this age group...
FDA approves OXYTROL® FOR WOMEN
25 January 2013 | By Merck
Merck announced that the U.S. FDA has approved OXYTROL FOR WOMEN, the first and only over-the-counter treatment for overactive bladder in women...
Amgen backs States’ efforts to enact biosimilar legislation that allows for substitution and supports patient safety
25 January 2013 | By Amgen
"Amgen endorses state policies that would put patients first..."
Heinrich Meintrup becomes Group Managing Director of GEA Pharma Systems
24 January 2013 | By The Words Workshop Ltd
On 1 January 2013 Heinrich Meintrup took over his new role as Group Managing Director...
Anders Hamsten to be installed as new president of Karolinska Institutet
24 January 2013 | By Cision
“Anders Hamsten will be an excellent president. It is also very gratifying that he has solid support from within the organisation”
FDA approves new use of Avastin plus chemotherapy for people with metastatic colorectal cancer
24 January 2013 | By Roche
Roche announced that the US FDA approved a new use of Avastin...
Pfizer announces top-line efficacy results from a Phase 4 study of PRISTIQ® (desvenlafaxine)
24 January 2013 | By Pfizer
New data add to evidence supporting PRISTIQ as a treatment option for MDD...
GSK appoints Hans Wijers to its Board as a Non-Executive Director
24 January 2013 | By GlaxoSmithKline
GlaxoSmithKline announced the appointment of Hans Wijers to its Board as a Non-Executive Director, effective 1st April 2013...
Gilead initiates Phase 3 clinical program for tenofovir alafenamide
24 January 2013 | By Gilead Sciences
“We are pleased to move TAF into Phase 3 clinical research...”
Biogen Idec announces positive top-line results from Phase 3 study of peginterferon beta-1a in multiple sclerosis
24 January 2013 | By Biogen Idec
Biogen Idec released the primary efficacy analysis and safety data from its Phase 3 pivotal clinical trial...
Novartis drug Exjade® first treatment approved by FDA
23 January 2013 | By Novartis
Novartis drug Exjade® first treatment approved by FDA for chronic iron overload in patients with non-transfusion-dependent thalassemia...
Recent advances in Microbiology – Rapid Mycoplasma Test
22 January 2013 | By SMi Group
SMi’s Pharmaceutical Microbiology conference taking place on the 30th & 31st January London...
ABRAXANE® (nab-paclitaxel) plus gemcitabine demonstrates survival advantage in Phase III study of patients with advanced pancreatic cancer1
22 January 2013 | By Weber Shandwick
Celgene UK and Ireland announced that its phase III clinical trial of ABRAXANE® (nab-paclitaxel) in combination with gemcitabine in treatment-naïve patients with metastatic pancreatic cancer demonstrated a statistically significant improvement in overall survival...
